Full US approval of Gilead’s Tecartus was the only positive decision last month.
ApexOnco Front Page
Recent articles
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA mutants, as well as wild types.
An actinium-based backup and Werner helicase inhibitor are notable absences.
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
But the Astra/Daiichi ADC stumbles in lung cancer.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
The company is starting four new pivotal trials this year.
